FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Anticoagulation in obese patients: challenges and strategies
2048PDF: 544HTML: 314XML: 200 -
The key to fibrinolysis and thrombolysis
1713PDF: 532HTML: 267 -
PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety M. D’uva1,2, G. La Barba1, G. Montanaro1, M. Di Ianni1,2, P. Ranalli1,2 | 1Hematology Unit, S. Spirito Hospital, Pescara; 2Department of Medicine and Aging Sciences, D’Annunzio University, Chieti, Italy
666PDF: 32 -
CO105 | THALIDOMIDE FOR RECURRENT GASTROINTESTINAL BLEEDING IN RARE BLEEDING DISORDERS AND VENOUS MALFORMATIONS: A MONOCENTRIC EXPERIENCE M. De Siati1|2, F.G. Perretta1|2, F. Ricci1|2, A. Ferretti1, M. Comand1|2, S. Sorrentino1, L. D’Innocenzo1|2, D. Feliciani2, B. Funaro2, M.E. Riccioni3, A. Gasbarrini2|4, E. De Candia1|2 | 1UOSD Malattie Emorragiche e Trombotiche, Fondazione Policlinico Agostino Gemelli IRCCS, Roma 00168, Italy; 2Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Roma, Italy; 3Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli, Roma 00168, Italy; 4Department of Medical and Surgical Sciences, Digestive Disease Center, Universitary Policlinic Agostino Gemelli Foundation IRCCS, Roma, Italy
67PDF: 28 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
540PDF: 126 -
OC06 | PRIMARY THROMBOPROPHYLAXIS IN ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA UNDERGOING SYSTEMIC ANTICANCER TREATMENT: A CANCER-CENTER COHORT STUDY ON CLINICAL PRACTICE AND OUTCOMES F. Haque1|2, A. Adekeye1|2, Z. Mohtashim2, K. Page1, M. Goodman1, A. Maraveyas 1|2 | 1Hull University Teaching Hospital NHS Trust, UK; 2Hull York Medical School, UK
499PDF: 112 -
CO-19 | A CASE OF LOSS OF EFFICACY OF EMICIZUMAB AFTER 6 YEARS OF REGULAR USE M.R. Fasulo1, I. Quaglia1, A. Colombo1, C. Lodigiani1, M.E. Mancuso1|2 | 1Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy
66PDF: 23 -
CO092 | FOSTAMATINIB IN CHRONIC IMMUNE THROMBOCYTOPENIA: A REAL-WORLD MONOCENTRIC EXPERIENCE M. Biglietto, S. Sorella, S. Ligia, S. Santostefano, R. Celia, R. Mormile, E. Baldacci, A. Chistolini, C. Santoro | Sapienza University of Roma, Italy
72PDF: 31 -
CO-55 | DEVELOPMENT OF ENGINEERED LONG-ACTING BYPASSING FX VIA ALBUMIN FUSION FOR HEMOPHILIA WITH INHIBITORS A. Martucci1, R. Tarantino1, K.H. Aaen2, M. Pinotti1, J.T. Andersen2, A. Branchini1 | 1Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy; 2Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Norway
72PDF: 21 -
PO074 | DEVELOPMENT OF INNOVATIVE LONG-ACTING FACTOR IX AND FACTOR X VARIANTS VIA CONDITIONAL ALBUMIN FUSION A. Martucci1, R. Tarantino1, K.H. Aaen2, M. Pinotti1, J.T. Andersen2, A. Branchini1 | 1Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy; 2Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway
75PDF: 20 -
CO062 | REDUCED-DOSE DOACs IN EXTENDED TREATMENT OF CANCER-ASSOCIATED THROMBOSIS (RED-CAT): INTERIM ANALYSIS FROM A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY (COORDINATING CENTER DATA) S. Bergonzi1|2|3, A. Ghigo4, L. Carpisassi4, G. Murante1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|5, R. Pastorino3|5, F. Bocchi3|5, A. Porreca6|7, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, Università di Torino, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Division of Internal Medicine, AOU Città della Salute e della Scienza, Università di Torino, Italy; 5Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Università di Torino, Italy; 6Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Roma, Italy; 7Clinical and Molecular Epidemiology, IRCCS San Raffaele, Roma, Italy
54PDF: 32 -
PO102 | EFFICACY AND SAFETY OF VISCOELASTIC TESTING–GUIDED TRANSFUSION IN CIRRHOSIS UNDERGOING INVASIVE PROCEDURES: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS A. Boccatonda1, E. Campello2, A. Napolitano2, C. Simion2, C. Serra1, P. Simioni2 | 1Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Via Massarenti N 9, 40138, Bologna, Italy; 2First Chiar of Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University Hospital of Padova, 35128, Padova, Italy
49PDF: 21 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
659PDF: 28 -
CO-64 | REAPPRAISAL OF DESMOPRESSIN FOR MANAGEMENT OF MILD/MODERATE VON WILLEBRAND DISEASE: RESULTS OF A RETROSPECTIVE ANALYSIS IN 127 ITALIAN PATIENTS SUGGEST FURTHER ORGANIZATION OF PROSPECTIVE OBSERVATIONAL STUDIES TO PREDICT DESMOPRESSIN FAILURE WITH IMMEDIATE VWF CONCENTRATES REQUIREMENT A.B. Federici1, G. Castaman2 | 1Ematologia e Medicina Trasfusionale, Ospedale Luigi Sacco, Polo Didattico Università di Milano, Italy; 2Centro Emofilia e Malattie Emorragiche Regione Toscana, Ospedale Careggi, Firenze, Italy
60PDF: 21 -
OC10 | FROM DESIGN TO CLINICAL PHASE 3 IN ONCOLOGY: CD13-TARGETED TISSUE FACTOR AND TUMOR INFARCTION W.E. Berdel, C. Schwöppe, C. Brand, K. Hessling, A.F. Berdel, T. Kessler, G. Lenz, R.M. Mesters, C. Schliemann | Department of Medicine A, University Hospital, Muenster, Germany
502PDF: 105 -
PO20 | Impact of endovascular treatment on functional outcome in ischemic stroke: a real-world retrospective study M.G. Mosconi1, G. Maraziti1, M. Paciaroni2, J. Fagotti3, V. Caso1 | 1Azienda Ospedaliera di Perugia; 2Università degli Studi di Ferrara; 3Ospedale San Giovanni Battista, Foligno (PG), Italy
678PDF: 26 -
PO31 | MIGRATORY SUPERFICIAL THROMBOPHLEBITIS REFRACTORY TO APIXABAN IN A PATIENT WITH LUNG ADENOCARCINOMA I. Goldberg1|2, P. Raanani1|2|3, G. Spectre1|2 | 1Institute of Hematology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel; 2Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; 3Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel
510PDF: 104 -
PO129 | CLINICAL BENEFIT OF RECOMBINANT ADAMTS13 IN CTTP ASSOCIATED WITH HOMOZYGOUS PD173G MUTATION AND UNDETECTABLE ACTIVITY M. Sacco1, S. Lancellotti1, M. Basso1, R. De Cristofaro1|2 | 1Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy; 2Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica S. Cuore, Roma, Italy
49PDF: 25 -
CO-61 | REAL-WORLD IMPLEMENTATION OF GENE THERAPY FOR HEMOPHILIA: A SHARED PATHWAY AMONG HEALTHCARE AUTHORITY, SPECIALIST CENTERS AND PATIENT ORGANIZATIONS IN THE EMILIA-ROMAGNA REGION A. Coppola1, L. Valdrè2, C. Biasoli3, E. Ferri Grazzi4, E. Rozzi5, M. Volta5, R. Giroldini6, A. Tagliaferri1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2SSD Malattie Emorragiche Congenite, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; 3SSI Presa in Carico delle Malattie Emorragiche e Tromboemboliche, AUSL Romagna, Ospedale Bufalini, Cesena, Italy; 4FEDRED, Federazione delle Associazioni Emofilici della Regione Emilia Romagna, Italy; 5Servizio Assistenza Ospedaliera, Malattie Rare, Direzione Generale Cura della Persona, Salute e Welfare, Regione Emilia Romagna, Italy; 6Area Governo del Farmaco e Dispositivi Medici, Direzione Generale Cura della Persona, Salute e Welfare, Regione Emilia Romagna, Italy
64PDF: 20 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
948PDF: 123HTML: 139Supplementary: 79Appendix: 81 -
CO06 | Recurrences of catheter associated upper extremity deep vein thrombosis in cancer: a two year prospective study with enoxaparin M. Sartori, A. Trentini, S. Cavara, L. Borgese, M. Soldati, B. Cosmi | Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
692PDF: 36 -
PO65 | Utilization of emicizumab in acquired hemophilia A: a case report C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, G. D’errico, L. Jr Valletta, M. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
642PDF: 36 -
CO-23 | PERIOPERATIVE MANAGEMENT OF MILD-TO-MODERATE HEMOPHILIA: A COMPARATIVE STUDY OF EXTENDED HALF-LIFE VERSUS STANDARD HALF-LIFE CONCENTRATES ON CLINICAL OUTCOMES AND FACTOR CONSUMPTION M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, S. Bergonzi1|2|3, G. Murante1|2|3, A. Valpreda4, R. Pastorino1|3, F. Bocchi1|3, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, University of Turin, Italy
66PDF: 21 -
CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience A. Hoxha1, E. Campello1, F. Ahmad2, L. Spiezia1, P. Scarinzi1, G. Gobbo1, S. Gavasso1, F. Sartorello1, C. Simion1, E. Zanon1, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED; 2Department of Statistical Sciences) University of Padova, Italy
774PDF: 29 -
PO12 | Characterisation and real word clinical data of HEM006, a newly formulated intranasal spray desmopressin (DDAVP) to address a global treatment gap G. De Giorgi1, A. Gringeri2, R. Franceschini1, A. Koganti3 | 1Hemorare Srl, Italy; 2Fondazione Charta, Milan, Italy; 3Quenya LLC, USA
591PDF: 19 -
PO079 | PERIOPERATIVE MANAGEMENT OF MILD-TO-MODERATE HEMOPHILIA: A COMPARATIVE STUDY OF EXTENDED HALF-LIFE VERSUS STANDARD HALF-LIFE CONCENTRATES ON CLINICAL OUTCOMES AND FACTOR CONSUMPTION M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, S. Bergonzi1|2|3, G. Murante1|2|3, A. Valpreda4, R. Pastorino1|3, F. Bocchi1|3, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, Università di Torino, Torino, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Torino, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Università di Torino, Torino, Italy
60PDF: 25 -
PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
767PDF: 35 -
PO125 | ROMIPLOSTIM FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA IN ADVANCED SOLID TUMORS: A SINGLE-CENTER EXPERIENCE G. Giustini1, A. Baffioni1, C. Giubbilei1, A.M. Vannucchi2, V. Carrai3 | 1SOD Ematologia, Università degli studi di Firenze, Italy; 2Center for Research and Innovation of Myeloproliferative Neoplasms, SOD Ematologia, AOU Careggi, Università degli studi di Firenze, Italy; 3SOD Ematologia, Dipartimento di Oncologia, AOU Careggi, Firenze, Italy
46PDF: 24 -
PO50 | SUB-ANALYSIS OF INTERIM RESULTS FROM A PHASE 2 STUDY INVESTIGATING REGN9933A2 AND REGN7508CAT FOR THE PREVENTION OF CONTACT-MEDIATED VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER UNDERGOING PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT (ROXI-CATH) J. Zwicker1,2, A.P. Kithcart3, J. Kaplan3, Y-C. Cheng3, J.G. Raya3, J. Xiao3, S. Li3, K. Musgrave4, D.E. Gutstein3, G. Piazza5 | 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Weill Cornell Medical Center, New York, NY, USA; 3Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 4Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 5Brigham and Women’s Hospital, Boston, MA, USA
535PDF: 131 -
PO55 | Evaluation of safety and efficacy of emicizumab prophylaxis in pediatric patients with hemophilia A – a single centre experience M.L. Tramontano, M. Coppola, S. Coppola, M. Schiavulli | UOSD Centro Regionale Pediatrico Malattie della Coagulazione, Santobono Pausilipon Children Hospital, AORN, Napoli, Italy
585PDF: 34 -
PO08 | Efficacy and safety of thromboprophylaxis in hospitalized hematological patients: a monocenter retrospective study S. Cordella1,2, V. Coluccio3, M. Luppi1, M. Marietta1 | 1Department of Medical and Surgical Sciences, Section of Hematology. University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena; 2Clinical and Experimental Medicine PhD Programme, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena; 3Department of Hematology, Unità Sanitaria Locale di Modena, Italy
590PDF: 21 -
CO-17 | EMBODIED SELF-MANAGEMENT IN HEMOPHILIA: PSYCHOSOMATIC EFFECTS OF A SUPERVISED PHYSICAL ACTIVITY PROGRAM F. Valeri1, M. Miniotti2, M.G. Bailon2, C. Dainese1, B. Bruno3, P. Leombruni2, A. Borchiellini1 | 1Regional Centre for Haemorrhagic and Thrombotic Disease, Hematology Division, AOU Città della Salute e della Scienza, Torino, Italy; 2Departement of Neurosciences Rita Levi Montalcini, University of Turin, Italy; 3Division of Hematology, AOU Città della Salute e della Scienza, Department of Molecular Biotechnology and Health sciences, University of Turin, Italy
55PDF: 19 -
PO107 | OUTCOME AND RISK OF CANCER IN SUPERFICIAL VENOUS THROMBOSIS WITH AND WITHOUT VARICOSE VEINS M. Sartori, E. Zanata, S. Cavara, M. Soldati, B. Cosmi | Angiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
62PDF: 25 -
CO-44 | EVALUATION OF THE DEVIATION BETWEEN PRESCRIBED AND RECOMMENDED EMICIZUMAB DOSING IN PATIENTS WITH CONGENITAL HEMOPHILIA A A.C. Giuffrida1, S. Abeysinghe Gunawardhana1, S. Amato2, F. Casoli2, C. Recchi2, M. Saggioro2, E. Bonetti3, M. Bodini1, G. Poli2 | 1Centro Emofilia, UOC Medicina Trasfusionale, AOUI Verona, Italy; 2UOC Laboratorio Analisi, AOUI Verona, Italy; 3UOC Oncoematologia Pediatrica, AOUI Verona, Italy
57PDF: 24 -
PO92 | Challenging management of portal vein thrombosis in a cirrhotic patient on hormone therapy after breast cancer L. Jr Valletta, C. De Luca, M. Aversano, C. Caputo, E. Cimino, P. Conca, A. Tufano, M.D. Di Minno | AOU Federico II Napoli, Italy
581PDF: 25 -
PO011 | A TWO CENTERS REAL-WORLD EXPERIENCE WITH ANTI-XA DIRECT ORAL ANTICOAGULANTS IN CANCER PATIENTS WITH UNUSUAL SITE VEIN THROMBOSIS U. Mazzarelli1, L. Agrelli1, A. Cirillo1, C. Caputo2, M. Romano2, R. Russo2, R. Guarrasi3, M. Triggiani1, A. Tufano2, A. Guida4 | 1Dipartimento di Medicina Interna, Università degli studi di Salerno, Italy; 2Dipartimento di Medicina Interna, Università degli studi di Napoli Federico II, Italy; 3UOC Clinica Oncologica; 4Centro per le malattie emorragiche congenite e malattie trombotiche AOU San Giovanni di Dio e Ruggi d'Aragona Salerno, Italy
68PDF: 30 -
PO36 | EXTENDED DURATION REDUCED DOSE ANTICOAGULATION IN CANCER-ASSOCIATED THROMBOSIS: A REAL-WORLD COHORT WITH LONG TERM FOLLOW UP A. Bhide1, I. Welding1, O. Ogunbiyi1, S. Hawkins2, E. Greenlay1, N. Prasannan1, J. Westwood1, M. Thomas1 | 1Department of Clinical Haematology, University College London Hospital, London; 2Data Clinic, University College London, UK; A. Bhide and I. Welding joint First Authors
505PDF: 121 -
PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis L. Gurgoglione, C.A. Piro, I. Scortechini, I. Battilà, M.C. Merlo, A. R. Scortechini, S. Rupoli, A. Poloni | Hematology Unit, AOU delle Marche-Università Politecnica delle Marche, Italy
535PDF: 22 -
CO-72 | HEREDITARY FACTOR X DEFICIENCY UNMASKED BY NECROTIZING HEMORRHAGIC PANCREATITIS: A CASE REPORT M. Leotta, A. Strangio, A. Ierardi, R.C. Santoro | Hemophilia Treatment Center AOU Dulbecco, Catanzaro, Italy
51PDF: 23 -
CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients A. Cottonaro1, S. Akula1, B. Pollio2, I. Ricca2, T. Martini2, J. Agnelli Giacchello3, P. Sciancalepore3, R. Santi3, A. Follenzi1,3, S. Merlin1 | 1Università del Piemonte Orientale, Health Sciences, Novara; 2A.O. Città della Salute e della Scienza, SIMT Immunohematology and Transfusion Medicine Service, Diagnostic Department, Torino; 3Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
658PDF: 24 -
PO064 | CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA: HOW TO MANAGE? - A CASE FROM REAL WORLD N. Galli1, S. Giuliano2, S. Grasso3, B. Montaruli4, D. Cilloni1, G. Giuffrida3, P. Sivera4 | 1Department of Clinical and Biological Sciences, University of Turin, Italy; 2Department of Medical Sciences, University of Turin, Italy; 3AOU Policlinico “G. Rodolico San Marco”, Catania, Italy; 4Haematology and Cellular Therapies Unit, A. O. Ordine Mauriziano di Torino, Italy
48PDF: 24 -
PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy
652PDF: 36 -
CO050 | INTERACTION BETWEEN DIRECT ORAL ANTICOAGULANTS AND ANTIEPILEPTIC DRUGS: A MULTICENTER OBSERVATIONAL STUDY A. Lipari1, S. Sorrentino1, M. De Siati1, L. D'Innocenzo1, A. Ferretti1, D. Menichelli2, V. Cammisotto2, P. Pignatelli2, G. Ragna3, MC. Vedovati3, C. Becattini3, G. Frisullo4, V. Forte5, T. Pirozzi1, L. Di Gennaro1, M. Basso1, E. De Candia1 | 1Unit of Haemostasis and Thrombosis Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 2Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Roma, Italy; 3Department of Internal and Cardiovascular Medicine and Stroke Unit, University of Perugia, Perugia, Italy; 4Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 5Hematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, Italy
69PDF: 30 -
PO07 | PLATELET INHIBITION BY THE NOVEL NITRIC OXIDE-DONOR NITROSOOXYPROPANOL M. Lindkvist, J. Jakobsson, F. Lynfeldt, B. Sandberg, K. Fransén, K. Nilsson, M. Grenegård | Cardiovascular Research Centre, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
456PDF: 111 -
PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
640PDF: 31 -
CO-34 | SIMPLIFIED PERIOPERATIVE MANAGEMENT WITH N8-GP (TUROCTOCOG ALFA PEGOL) IN MAJOR ABDOMINAL SURGERY IN MILD HEMOPHILIA A WITH SEVERE BLEEDING PHENOTYPE: A CASE REPORT J. Di Paolo, R. Malizia, M. Luongo, P. Massaro, M. Di Mascio, S. Verna | Immunohematology Service, ASL 02 Abruzzo, Chieti, Italy
47PDF: 19 -
PO91 | Disseminated intravascular coagulation with deep vein thrombosis in a frail patient: an extreme manifestation triggered by sepsis during SGLT2i therapy M. Vacca1, M.V. Cherchi1, S. Che1, G.A.M.L. Costanzo2, D. Firinu2, M. Mantega1, S. Del Giacco2 | 1Ospedale Sirai, ASL Sulcis, 2Università degli Studi di Cagliari, Italy
814PDF: 25 -
PO005 | EXTENDED ANTICOAGULATION WITH DOACS IN PATIENTS AFFECTED BY HEMATOLOGIC MALIGNANCIES AND VENOUS THROMBOEMBOLISM: DOES LOW DOSE FIT ALL? M. Biglietto, S. Sorella, L.V. Cappelli, B. Mandelli, D. Kasmi, E. Baldacci, A. Chistolini | Sapienza University of Roma, Italy
41PDF: 37 -
PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS L. Gurgoglione1, G. Gini1, S. Rupoli1, A. Poloni1|2 | 1Hematology, AOU delle Marche, Ancona; 2Università Politecnica delle Marche, Ancona, Italy
522PDF: 99 -
PO158 | A RARE CASE OF ISCHEMIC STROKE: CAROTID WEBS C. Mazzei, I. Costanzo, D. Fumarulo, S. Bernardi, G. Trinchera, M. Littera, M. Mazzetti, C. Tamburini | Medicina Interna Interdisciplinare, A.O.U. Careggi, Firenze, Italy
83PDF: 27 -
CO30 | Joint prosthetic surgery in patients with hemophilia A: clinical-functional outcomes and quality of life E. Zanon1, A. Napolitano1, A. Berizzi2, P. Simioni1 | 1Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua; 2Orthopedics and Traumatology Unit, University-Hospital of Padua Medical School, Padua, Italy
708PDF: 41 -
PO048 | EFFICACY OF RITUXIMAB TREATMENT IN A CASE OF A RELAPSED AND REFRACTORY ACQUIRED VON WILLEBRAND DISEASE SECONDARY TO PRIMARY CUTANEOUS MARGINAL ZONE B-CELL LYMPHOMA L. Gurgoglione1, F. Saladino2, E. Morsia2, N. Viola3, S. Rupoli1, A. Poloni2 | 1Clinical Hematology, AOU delle Marche, Ancona, Italy; 2Università Politecnica delle Marche, Ancona, Italy; 3Clinical Immulogy, AOU delle Marche, Ancona, Italy
56PDF: 30 -
PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven1|9, E. Van Gansewinkel5|10, J. De Bruijne2, F. Eskens3, D. De Groot4, K. Hermans5, N. Mohammad6, F. Van Vilsteren7, C. Verslype8, W. Moris9, M. Roest10, B. De Laat10 , J. De Vos-Geelen5, M. Kramer1|9 | 1Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 2Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; 3Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; 4Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; 5Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 6Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; 7Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; 8Digestive Oncology, University Hospitals Leuven, Belgium; 9Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; 10Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group
458PDF: 102 -
PO67 | Pancreatic cancer in a 71-year-old severe hemophilia A patient with inhibitors and sustained zero bleeding during emicizumab prophylaxis M. Biglietto, A.L. Faccini, S. Sorella, E. Crisanti, M. Antonacci, A. Taglietti, M. Gherardini, A. Tirnetta, S. Ligia, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
679PDF: 37 -
CO049 | RANDOMIZED CONTROLLED TRIAL TO IDENTIFY THE OPTIMAL SCHEME OF HEPARIN FOR TREATMENT OF DEEP VEIN THROMBOSIS IN PREGNANCY E. Grandone1|3, E. Antonucci2, A. de Laurenzo1, L. Latino1, M. Mastroianno1, G. Tiscia1, M. Margaglione3, P. Prandoni2 | 1IRCCS Casa Sollievo della Sofferenza, S.Giovanni Rotondo, Italy; 2Fondazione Arianna, Italy; 3Università di Foggia, Italy
71PDF: 33 -
PO089 | A RISK-ADAPTED, MULTIDISCIPLINARY CONSENSUS FOR ADULT ITP MANAGEMENT: BRIDGING GUIDELINES AND REAL-WORLD PRACTICE A. Votto1, E. Pacini2, G. Giustini3, I. Rina1, S. Galimberti1 | 1Department of Clinical and Experimental Medicine, University of Pisa, Italy; 2Hematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Italy; 3Hematology Unit, AOU Careggi, Firenze, Italy
62PDF: 26 -
CO-27 | INNOVATIVE USE OF EPTACOG BETA TO TREAT ACUTE ELBOW HEMARTHROSIS IN A PEDIATRIC PATIENT WITH HEMOPHILIA B AND A HISTORY OF INHIBITORS, UNDERGOING SECONDARY PROPHYLAXIS WITH CONCIZUMAB L. Laterza1, P. Giordano2, G. Lassandro2 | 1University of Bari "Aldo Moro", Interdisciplinary Department of Medicine, Bari, Italy; 2Pediatric Haemophilia Center-AOUC Pol. Giovanni XXXIII, University of Bari “Aldo Moro”, Bari, Italy
69PDF: 22 -
PO89 | Apixaban for secondary prevention of venous thromboembolism in hemodialysis patients: pharmacokinetic profile and safety outcomes S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padua, Italy
869PDF: 20 -
CO05 | Long-term management of upper extremity catheter-related thrombosis in female patients with cancer: a retrospective cohort study Chiara Cavallaro1,2, Paolo Santini1,2, Laura Leoni3, Carolina Mosoni1,2, Silvia D’Ambrosio1,2, Francesco Mancinetti1,2, Nicola Coletta1,2, Michela Iorio1,2, Angelo Porfidia1,2, Alessandro D’Errico1,2, Rosa Talerico1,2, Roberto Pola1,2 | 1Department of Aging, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; 2Università Cattolica del Sacro Cuore, Rome; 3Vita-Salute University, San Raffaele Hospital IRCCS, Milan, Italy
688PDF: 34 -
PO045 | FROM PROPHYLAXIS TO ENDOGENOUS CONTROL: A SIX-MONTH REAL-WORLD EXPERIENCE WITH VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY M. Basso1, A. Ferretti1, M. Sacco1, S. Lancellotti1, T. Pirozzi1, L. Di Gennaro1, R. De Cristofaro1|2 | 1Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario Gemelli IRCCS, Italy; 2Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica S. Cuore, Roma, Italy
55PDF: 32 -
CO015 | EVOLUTION OF ANTICOAGULANT THERAPY FOR CANCER-ASSOCIATED THROMBOSIS: THE START2 REGISTRY ONCO-VTE LONGITUDINAL STUDY M. Marchetti1|2, T. Zollner1|2, O.C. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Roma, Roma, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Torino, Italy; 7Department of Medicine, University of Padua, Padova, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Roma, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
156PDF: 25 -
PO14 | Searching for safer rescue immunosuppressive therapy protocols in acquired hemophilia A: two case reports G. Quintavalle1, I.M. Tassoni1, B.M. Roccon1, G. Lucchini2, F. Magalini2, M. Zardo2, R. Rossi3, C. Cattabiani3, A. Tagliaferri1, A. Coppola1 | 1SSD Centro HUB Emofilia e MEC; 2UOS Medicina Interna e Reumatologia; 3UO Diagnostica Ematochimica, Azienda Ospedaliero Universitaria, Parma, Italy
568PDF: 35 -
PO085 | ACQUIRED HEMOPHILIA A IN THE SURGICAL PATIENT: DIAGNOSTIC AND THERAPEUTIC COMPLEXITY M. Luongo1, P. Massaro1, M. Di Mascio1, P.G. Simeone2, F. Santilli2, S. Verna1 | 1Immunohematology Service, Asl 02 Abruzzo, Chieti, Italy; 2Department of Medicine and Aging Sciences, and Center for Advanced Studies and Technology, “G. d’Annunzio” University of Chieti–Pescara, Italy
58PDF: 24 -
PO88 | Bacterial lysate “lantigen B” induces proliferation of B and NK cells and the release of related cytokines M. Alfonsetti1, R. Liani1, P. Di Mattia3, M. Tredicine4, F. Papa3, Q. Niu5, M. Di Gioacchino2, F. Santilli1,3 | 1Department of Medicine and Aging, Center for Advanced Studies and Technology, University of Chieti, Italy; 2Institute for Clinical Immunotherapy and Advanced Biological Treatments, Pescara, Italy; 3Specialization School of Allergy and Clinical Immunology, G. d’Annunzio University, Chieti, Italy; 4Department of Medical, Oral, and Biotechnology Science, University G. d’Annunzio, Chieti-Pescara, Chieti, Italy; 5Department of Occupational Health, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China
758PDF: 24 -
CO094 | ASSESSMENT OF THE MINIMAL EFFECTIVE DOSE OF AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTER REAL-WORLD STUDY A. Baffioni1, C. Giubbilei1, G. Giustini1, A.M. Vannucchi2, V. Carrai3 | 1SOD Ematologia, Università degli studi di Firenze, Italy; 2Center for Innovation and Research in Myeloproliferative Neoplasms, SOD Ematologia, Azienda Ospedaliera Universitaria Careggi, Università degli studi di Firenze, Italy; 3SOD Ematologia, Dipartimento di Oncologia, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
58PDF: 29 -
PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze 1, A. Vorobev 1, J. Khizroeva 1, A. Solopova 1, M. Tretyakova 1, N. Gashimova 1, K. Grigoreva 1, A. Khisamieva 1, J. Gris 1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
484PDF: 101 -
PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy
639PDF: 28 -
PO126 | HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS FOR LONG-TERM PREVENTION OF RECURRENT GASTROINTESTINAL BLEEDING IN A PATIENT WITH ACQUIRED VON WILLEBRAND SYNDROME ASSOCIATED WITH MGUS R. Benedetti1, G. Quintavalle2, V. Della Corte1, M.I. Tassoni1, B.M. Roccon1, D. Imberti1, A. Coppola2 | 1Centro Emostasi e Trombosi, Medicina Interna, Azienda USL di Piacenza, Italy; 2SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy
52PDF: 21 -
CO-60 | A TURNING POINT IN THE MANAGEMENT OF HEMOPHILIA B WITH INHIBITORS: OUTCOMES OF CONCIZUMAB PROPHYLAXIS IN TWO CHILDREN FROM EXPLORER10 G. Quintavalle1, A. Matichecchia1, M.I. Tassoni1, B.M. Roccon1, F. Riccardi1, R.P. Serra2, A. Tiri2, P. Bertolini2, A. Tagliaferri1, A. Coppola1 | 1Regional Hub Center for Hemophilia and Congenital Bleeding Disorders, University Hospital of Parma, Italy; 2Pediatric Hematology-Oncology Unit, University Hospital of Parma, Italy
68PDF: 24 -
PO043 | MULTICENTRE REAL‑WORLD EXPERIENCE OF EMICIZUMAB PROPHYLAXIS IN AN ITALIAN COHORT OF 49 CHILDREN WITH SEVERE HEMOPHILIA A - EMIPED STUDY L. Pieri1, B. Pollio2, P. Giordano3, G. Lassandro4, S. Linari1, R. Pasquino1, E. Piellucci1, MC. Di Stefano1, F. Demartis1, R. Fjerza1, G. Castaman1 | 1Center for Bleeding Disorders, Careggi University Hospital, Firenze, Italy; 2Center for Inherited Bleeding and Thrombotic Disorders, Transfusion Medicine, "Regina Margherita" Children Hospital, Torino, Italy; 3Department of Interdisciplinary of Medicine, University of Bari 'Aldo Moro', Bari, Italy; 4General and Specialised Pediatrics Unit, "Giovanni XXIII" Hospital, University of Bari, Bari, Italy
61PDF: 26 -
PO52 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC AND TIME-TO-EVENT MODELING SUPPORT SUSTAINED FACTOR XI INHIBITION AND SUPERIOR POST-OPERATIVE VENOUS THROMBOEMBOLISM PREVENTION WITH REGN7508CAT O. Milberg1, H. Abdallah1, R.K. Lokken2, R. Dingman1, K.A. Meagher1, P. Banerjee1, M.E. Burczynski1, E. Marin1, A.P. Kithcart1, D.E. Gutstein1 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Allucent, Cary, NC, USA
536PDF: 119 -
PO59 | Efficacy and safety of different anticoagulant treatment regimens for isolated internal jugular vein thrombosis: a case series A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, S. Marucci2, D. Menichelli1, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
712PDF: 43 -
CO011 | GENERATION OF A TARGETING NON-BLOCKING TISSUE FACTOR ANTIBODY FOR SAFE AND EFFICACIOUS CANCER TREATMENTS A. Metelli1, P. Nisticò1, J. Wrangle2 | 1IRCCS Regina Elena National Cancer Institute, Roma, Italy; 2Medical University of South Carolina, Charleston, USA
151PDF: 21 -
PO28 | CLINICAL IMPLICATIONS OF ANTICOAGULANT DRUG INTERACTIONS WITH TARGETED AND IMMUNE THERAPIES IN ONCOLOGY: A CONTEMPORARY RISK STRATIFICATION FRAMEWORK D. Dhami1, C. Solowiej Singh 1, M. Dhami 2 | 1Abrazo Internal Medicine Residency; 2Eastern Connecticut Hematology Oncology, Norwich, CT, USA
598PDF: 106 -
CO03 | Early discharge and home treatment of low-risk pulmonary embolism: a cohort study E. Ruggeri1, L. Vulcano1, W. Ageno2, F. Cortellaro3, M.P. Donadini3,4 | 1Scuola di Medicina, Università degli Studi dell’Insubria, Varese; 2Dipartimento di Medicina, Università degli Studi di Padova; 3Pronto Soccorso e Medicina d’Urgenza, Ospedale di Circolo, ASST Sette Laghi, Varese; 4Dipartimento di Medicina e Chirurgia, Università degli Studi dell’Insubria, Varese, Italy
684PDF: 34 -
PO041 | VARIABLE CLINICAL RESPONSE TO RECOMBINANT PORCINE FVIII IN ACQUIRED HAEMOPHILIA A: A TWO CASE EXPERIENCE WITH LABORATORY SUPPORTED MONITORING AM. Pizzini1, M. Bovara2, M. Sebastiani2, A. Fusco1, C. Fantoni1, M. Silingardi1, R. Mancini2, A. Coppola3 | 1Ambulatorio Emostasi & Trombosi, Dipartimento Medico - Ospedale Maggiore Bologna, Italy; 2Laboratorio Unico Metropolitano - Ospedale Maggiore Bologna, Italy; 3SDD Centro Hub Emofilia e MEC, Azienda Ospedaliero-Universitaria di Parma, Italy
67PDF: 28 -
CO005 | HEPATIC ENDOTHELIUM AS A SAFE AND DURABLE TARGET FOR LENTIVIRAL GENE THERAPY OF HEMOPHILIA A E. Borroni, F. Antony, S. Merlin, V. Kalandadze, C. Borsotti, A. Follenzi | Università del Piemonte Orientale, Novara, Italy
170PDF: 26 -
PO85 | Acute retinal ischemia in hemoglobin SC disease: a case report and review of the literature G. Bogoni1, A. Bertomoro1, E. Cosi1, M.T. Sartori1, R. Colombatti2, G. Reggiani2, M.P. Boaro2, I. Bertozzi1, P. Simioni1 | 1Clinica Medica 1, Dipartimento di Medicina DIMED, Università degli Studi di Padova; 2Clinica di Onco-Ematologia Pediatrica, Università degli Studi di Padova, Italy
706PDF: 24 -
CO078 | METABOLOMIC AND LIPOPROTEOMIC MODULATION FOLLOWING INCLISIRAN TREATMENT IN DYSLIPIDEMIC PATIENTS J. Patrussi1, A. Vignoli1|2, L. Tenori1|2, A. Sorrentino3, M. Berteotti3|4, E. Lotti4, F. Crudele4, G. Ciarrocca Taranta3, A.A. Rogolino4, G. Barbieri3, A.M. Gori3|4, R. Marcucci3|4 | 1Dep. of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy; 2Magnetic Resonance Center (CERM), University of Florence, Sesto Fiorentino, Italy; 3Dep. of Experimental and Clinical Medicine, University of Florence, Firenze, Italy; 4Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
64PDF: 19 -
PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti1|2, T. Zollner1|2, OC. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; 7Department of Medicine, University of Padua, Padua, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
451PDF: 95 -
PO34 | A negative oncologic follow up doesn’t always really mean no cancer: two case report of cancer-associated thrombotic microangiopathy E. Cosi, A. Bertomoro, G. Bogoni, I. Bertozzi, I. Cortella, P. Simioni | Clinica Medica ORI, Azienda Ospedale-Università Padova, DIDAS, Italy
614PDF: 35 -
PO108 | DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH VENOUS THROMBOEMBOLISM RECEIVING LONG-TERM IMMUNOSUPPRESSIVE THERAPY AFTER LIVER AND KIDNEY TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE U. Mazzarelli1, L. Agrelli1, A. Cirillo1, C. Crescenzo2, M. Triggiani1, A. Guida3 | 1Dipartimento di Medicina Interna, Università degli studi di Salerno, Italy; 2UOC Nefrologia e Trapianti di rene; 3Centro per le malattie emorragiche congenite e malattie trombotiche, AOU San Giovanni di Dio e Ruggi d'Aragona Salerno, Italy
71PDF: 30 -
CO-47 | JOINT ULTRASOUND FOLLOW-UP IN PEDIATRIC PATIENTS WITH HEMOPHILIA: A 12-YEAR PROSPECTIVE SINGLE-CENTER EXPERIENCE I. Ricca1, B. Borsellino2|3, T. Martini2, C. Martinoli4, B. Pollio2 | 1Transfusion Medicine, Ivrea Hospital, Ivrea, Italy; 2Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 3Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy; 4Department of Health Science DISSAL, University of Genova, Unit of Radiology and IRCCS San Martino Hospital, Genova, Italy
68PDF: 24 -
PO93 | Use of DOACS in heart transplantation recipients T. Marrazzo1, A. Delle Femine1, C. Amarelli2, R. Albisinni3 | 1UOC Medicina Interna e dei Trapianti, Ospedale Monaldi Azienda dei Colli, Napoli; 2UOSD CCH dei Trapianti, Ospedale Monaldi Azienda dei Colli, Napoli; 3UOC CCH Generale, Ospedale Monaldi Azienda dei Colli, Napoli, Italy
761PDF: 23 -
CS05 | Joint ultrasound follow-up in pediatric patients with haemophilia: a 12-year prospective single-center experience B. Borsellino1,2, B. Pollio1, C. Martinoli3, T. Martini1, R. Albiani1, I. Ricca1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Turin; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma; 3Department of Health Science DISSAL, University of Genoa, Unit of Radiology and IRCCS San Martino Hospital, Genoa, Italy
699PDF: 41 -
PO037 | TEMPO: A MOBILE HEALTH APPLICATION FOR PERSONALIZED MANAGEMENT OF HEMOPHILIA R. Gualtierotti1|2, F. Franco3, L. Bedogni4, M. Fassi1, A.A Giachi1, S. Mascetti5, M. Manzoni5, F. Poggi6, M. Pellegrini6, C. Suffritti1, F. Peyvandi1|2 | 1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; 2Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy; 3Department of Physics, Informatics and Mathematics (FIM), University of Modena and Reggio Emilia, Modena, Italy; 4Department of Sciences and Method for Engineering (DISMI), University of Modena and Reggio Emilia, Modena, Italy; 5Department of Computer Science, Università degli Studi di Milano, Milano, Italy; 6Institute for Cognitive Sciences and Technologies (ISTC), National Research Council (CNR), Bologna, Italy
73PDF: 34
